Intrinsic to the muscle, mechanistic evidence demonstrates the requirement of inhibitor of kappa B kinase beta (IKKβ) activation and the subsequent degradation of the inhibitor of kappa B alpha (IκBα) [7, 9, 10] for cancer-induced muscle atrophy and myogenic impairment. Here, NFKBIA is linked to cancer.